Allos Therapeutics Announces Stockholder Approval of Share Exchange
May 19 2005 - 5:46PM
PR Newswire (US)
Allos Therapeutics Announces Stockholder Approval of Share Exchange
WESTMINSTER, Colo., May 19 /PRNewswire-FirstCall/ -- Stockholders
of Allos Therapeutics, Inc. (NASDAQ:ALTH), voting at the Company's
2005 Annual Meeting of Stockholders held yesterday, May 18, 2005,
approved the issuance of shares of the Company's common stock upon
exchange of shares of the Company's Series A Exchangeable Preferred
Stock sold to Warburg Pincus Private Equity VIII, L.P. and certain
other investors in a financing transaction in March 2005. As a
result of such approval, the Company issued a total of 23,524,430
shares of common stock upon exchange of 2,352,443 shares of Series
A Exchangeable Preferred Stock. After giving effect to the share
exchange, the Company now has approximately 54.7 million shares of
common stock outstanding, of which Warburg Pincus owns
approximately 22.6 million shares, or 41.4%. The Company's
stockholders also approved all other matters brought before the
meeting, including the election of directors and ratification of
the Company's independent auditors. A full tally of the votes will
be published in the Company's quarterly report on Form 10-Q, which
will be filed with the Securities and Exchange Commission on or
about August 10, 2005. About Allos Therapeutics, Inc. Allos
Therapeutics, Inc. (NASDAQ:ALTH) is a biopharmaceutical company
focused on developing and commercializing innovative small molecule
therapeutics for the treatment of cancer. Our lead product
candidate, EFAPROXYN(TM) (efaproxiral), is a synthetic small
molecule designed to sensitize hypoxic, or oxygen-deprived, tumor
tissue during radiation therapy. EFAPROXYN is currently being
evaluated as an adjunct to whole brain radiation therapy in a
pivotal Phase 3 trial in women with brain metastases originating
from breast cancer. Our other product candidates are: PDX
(pralatrexate), a small molecule chemotherapeutic agent (DHFR
inhibitor) currently under investigation as both a single agent and
in combination therapy regimens in patients with non-small cell
lung cancer and Non-Hodgkin's lymphoma; and RH1, a small molecule
chemotherapeutic agent bioactivated by the enzyme DT-diaphorase
currently under evaluation in patients with advanced solid tumors.
For more information, visit the company's website at
http://www.allos.com/. Note: EFAPROXYN(TM) and the Allos logo are
trademarks of Allos Therapeutics, Inc. DATASOURCE: Allos
Therapeutics, Inc. CONTACT: Jennifer Neiman, Manager, Corporate
Communications of Allos Therapeutics, +1-720-540-5227, Web site:
http://www.allos.com/
Copyright
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Allos Therapeutics, Inc. (MM) (NASDAQ): 0 recent articles
More Allos Therapeutics - Common Stock (MM) News Articles